Colistin
Cystic Fibrosis
Floatz Rating
BBB72/100
Confidence
Indicative
Sponsor
Liverpool Heart and Chest Hospital NHS Foundation Trust
Modality
mixture
Development Phase
Phase 4 / Approved
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
72High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02894684CT.gov Aztreonam for Inhalation Solution (AZLI) for the Treatment of Exacerbations of Cystic Fibrosis | — | Completed | — | — | — |
NCT02918409CT.gov IV Colistin for Pulmonary Exacerbations: Improving Safety and Efficacy | — | Completed | — | — | — |
NCT03341741CT.gov Combined Dry Powder Tobramycin and Nebulized Colistin Inhalation in CF Patients | — | Completed | — | — | — |
NCT01035853CT.gov Sino-nasal Inhalation of Colistin in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Colonization | — | Completed | — | — | — |
NCT01400750CT.gov Comparison of 2 Treatment Regimens for Eradication of P Aeruginosa Infection in Children With Cystic Fibrosis | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Cystic Fibrosis
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Colistin (this asset) | Liverpool Heart and Chest Hospital NHS Foundation Trust | Approved | BBB · 72 |
| Tezacaftor | Vertex Pharmaceuticals Incorporated | P4 | A |
| Lumacaftor | Hospices Civils de Lyon | P4 | BBB |
| Ivacaftor | Meyer Children's Hospital IRCCS | P4 | BBB |
| Liprotamase | Anthera Pharmaceuticals | P4 | BBB |
| Elexacaftor | Meyer Children's Hospital IRCCS | P4 | BBB |
| vx-121 | Vertex Pharmaceuticals Incorporated | P3 | BBB |
| Azithromycin | Hospices Civils de Lyon | P4 | BBB |
| Aztreonam | Liverpool Heart and Chest Hospital NHS Foundation Trust | P4 | BB |
+42 more in the Cystic Fibrosis cohort
Other indications for Colistin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Pseudomonas Aeruginosa Infectious Disease | — | P2 | B · 57 |
| Colorectal Cancer | — | P4 | CCC · 54 |
| Hepatic Encephalopathy | — | Early P1 | C · 38 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Citation
Floatz Terminal. Colistin in Cystic Fibrosis. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/colistin-cystic-fibrosis
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →